Wednesday, February 10, 2010, 2:29PM AEST - The Australian Stockmarket closes in 1 hour and 36 minutes.
To create a watchlist or portfolio of shares, Register

ArQule Inc. (ARQL)

8:00AM AEST: 3.09 USD  Up 0.01 (0.32%)  
 MORE ON ARQL 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ArQule, Inc. (NGM:ARQL) Delayed quote dataEdit
Last Trade:3.09 USD
Trade Time: 8:00AM AEST
Change:Up 0.01 (0.32%)
Prev Close:3.08
Open:3.12
Bid:2.63 x 100
Ask:3.60 x 100
1y Target Est:7.70
Day's Range:3.06 - 3.13
52wk Range:2.62 - 6.38
Volume:126,276
Avg Vol (3m):178,330
Market Cap:138.09M
P/E (ttm):N/A
EPS (ttm):-0.81
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ARQL to Portfolio   Download Data

 HEADLINES 
ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer
Business Wire (Fri, Feb 5)
Local insider sales topped $279M in Q4
at bizjournals.com (Thu, Jan 14)
Acetylon Pharma lands $2M in financing
at bizjournals.com (Tue, Jan 12)
[$$] ArQule and Magellan Health Rise
at The Wall Street Journal Online (Wed, Dec 23)
[$$] Icahn Buys Stake in Take-Two, Boosting Small Tech Stocks
at The Wall Street Journal Online (Sat, Dec 19)
[$$] Rate, Credit Worries Hit Small-Caps
at The Wall Street Journal Online (Fri, Dec 18)
Positive Results for ARRY-380
Zacks.com (Tue, Dec 15)
ArQule, Inc.: Warming Up or Cooling Off?
at Motley Fool (Fri, Nov 20)
Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference
Business Wire (Tue, Nov 17)
ARQULE INC Financials
EDGAR Online Financials (Thu, Nov 12)
ARQULE INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
More Headlines for ARQL...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.84
EPS Est (in 2 years) (Dec-10) :-0.89
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices